In this issue:
SOLO1: long-term survival benefit to front-line Olaparib maintenance
ATHENA-MONO: front-line rucaparib efficacious regardless of HRD status
Aspirin linked to reduced risk for ovarian cancer
Could beta-blockers improve post-surgical survival?
KELIM as a complementary tool for predicting veliparib benefit
KELIM predicts response to first-line bevacizumab
Ovarian cancer mutational processes drive site-specific immune evasion
High THBS2 or TAGLN expression associated with poor survival in MOC
Pafolacianine allows intraoperative imaging of microlesions
Intraoperative blood transfusion does not adversely impact oncological outcomes
Please login below to download this issue (PDF)